Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 28,812 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Medication Clear all
Completed Not applicable Interventional

Better Pediatric Asthma Outcomes Through Chronic Care

NCT00355069
View directory record Official record
Conditions
Asthma
Interventions
electronic (computer based) provider feedback tool
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
5 Years to 17 Years
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 2 Interventional

Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)

NCT00042341
View directory record Official record
Conditions
Leukemia, Lymphoblastic, Acute, Pediatric
Interventions
clofarabine (IV formulation)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Up to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
14
States / cities
Los Angeles, California • Orange County, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction

NCT02517905
View directory record Official record
Conditions
Dental Pain
Interventions
Bupivacaine liposome, Placebo
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 26, 2026, 10:09 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Oct 26, 2026, 10:09 AM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

NCT07318805
View directory record Official record
Conditions
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions
PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Duarte, California • Grand Rapids, Michigan • Long Island City, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Results available

Subacromial Corticosteroid Injection for Hemiplegic Shoulder Pain

NCT00597766
View directory record Official record
Conditions
Shoulder Pain
Interventions
Lidocaine, Triamcinolone + Lidocaine
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Results available

Comparing Five Oral Analgesics for Treatment of Acute Pain in the Emergency Department (ED)

NCT03173456
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
oxycodone/APAP, hydrocodone/APAP, codeine/APAP, 400 ibuprofen/APAP, 800 ibuprofen/APAP
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Not applicable Interventional

Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) Demonstration Project

NCT01973556
View directory record Official record
Conditions
Hypertension
Interventions
Pharmacist-Physician Collaborative Medication Therapy Management
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 26, 2026, 10:09 AM EDT
Withdrawn Phase 4 Interventional

Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant

NCT03093740
View directory record Official record
Conditions
Renal Failure Chronic, Hepatitis C
Interventions
Zepatier, Zepatier plus Sofosbuvir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 26, 2026, 10:09 AM EDT
Terminated Phase 1 Interventional

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

NCT05631574
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Goodyear, Arizona • Encinitas, California • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 26, 2026, 10:09 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

NCT01821274
View directory record Official record
Conditions
Skin Irritation
Interventions
Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution o sodium lauryl sulfate (SLS), Saline 0.9%
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 26, 2026, 10:09 AM EDT
Recruiting Not applicable Interventional

Temporal Interference Brain Stimulation for Adults With Drug-Resistant Epilepsy Undergoing Stereo-EEG Monitoring

NCT07764718
View directory record Official record
Conditions
Drug-Resistant Focal Epilepsy
Interventions
Temporal Interference Stimulation, Direct Electrical Stimulation
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug

NCT04299490
View directory record Official record
Conditions
Sleep Disorder, Healthy
Interventions
Sleep Fragmentation, Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo), Sleep Continuity Disruption, Undisturbed Sleep
Behavioral · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 48 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

NCT05734690
View directory record Official record
Conditions
Heart Failure
Interventions
SGLT2i, beta blocker, ARNI, MRA, MTD, Education-First
Drug · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
503 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Results available

Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans

NCT01898013
View directory record Official record
Conditions
Lower Back Pain
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 26, 2026, 10:09 AM EDT
Active, not recruiting Not applicable Interventional

Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine

NCT07148713
View directory record Official record
Conditions
Nutrition, Type 2 Diabetes, T2DM, T2DM (Type 2 Diabetes Mellitus), Diabetes Education, Diabetes Type 2, Diabetes Mellitis
Interventions
CGM-Augmented FIM, FIM only
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 26, 2026, 10:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD

NCT04494360
View directory record Official record
Conditions
Healthy
Interventions
No intervention
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
830 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Hollywood, Florida • Lenexa, Kansas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 26, 2026, 10:09 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834360
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • La Mesa, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Provider Training in Increasing Patient Tobacco Cessation Counseling and Referrals for Patients With Cancer Undergoing Radiation Therapy

NCT03135782
View directory record Official record
Conditions
Breast Carcinoma, Caregiver, Head and Neck Carcinoma, Lung Carcinoma, Prostate Carcinoma, Tobacco Use
Interventions
Communication Skills Training, Medical Chart Review, Questionnaire Administration, Tobacco Cessation Counseling
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

NCT02133924
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
natalizumab, steroids
Drug
Lead sponsor
John Levine
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 2 Interventional

Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

NCT05556824
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
MHS-1031, Placebo
Drug · Other
Lead sponsor
Microbiome Health Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Lake City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Phase 3 Interventional

A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3

NCT00002123
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Didanosine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
83
States / cities
Birmingham, Alabama • Berkeley, California • Fresno, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Health Log: A Randomized Clinical Trial

NCT01913080
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Health Log
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 26, 2026, 10:09 AM EDT
Terminated Not applicable Interventional Results available

Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation

NCT01590979
View directory record Official record
Conditions
Atrial Fibrillation New Onset, Hemorrhage, Prolonged QTc Interval, Ventricular Tachycardia, Medical Care; Complications, Late Effect of Complications
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 26, 2026, 10:09 AM EDT